NCT01550289View on ClinicalTrials.gov

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2014

Conditions
DengueDengue FeverDengue Hemorrhagic Fever
Interventions
BIOLOGICAL

Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus

0.5 mL, Subcutaneous

BIOLOGICAL

Placebo: NaCl 0.9% solution

0.5 ml, Subcutaneous

Trial Locations (5)

110002

New Delhi

141008

Ludhiana

411018

Pune

560054

Bangalore

700073

Kolkata

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01550289 - Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India | Biotech Hunter | Biotech Hunter